Cullinan Therapeutics, Inc.
CGEM
$7.66
$0.081.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.44% | -35.05% | -9.28% | 8.07% | -0.28% |
| Total Depreciation and Amortization | -1.29% | -2.55% | -1.29% | 4.79% | 40.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.41% | 36.61% | 17.17% | -21.63% | -19.62% |
| Change in Net Operating Assets | 330.89% | 150.14% | -14.75% | 78.06% | 90.96% |
| Cash from Operations | -35.26% | -23.61% | -8.21% | 10.15% | 21.40% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.03% | -434.45% | -478.50% | -132.95% | -159.57% |
| Cash from Investing | 177.03% | -434.94% | -480.70% | -127.69% | -175.99% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.53% | 573.69% | 595.26% | 592.79% | 565.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 82.70% | -12,455.56% | -- | 86.64% | 88.61% |
| Cash from Financing | -98.76% | 561.98% | 553.21% | 3,389.05% | 2,860.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.39% | 105.07% | 73.27% | 120.94% | 87.34% |